Welcome to our dedicated page for Immix Biopharma news (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma stock.
Immix Biopharma Inc (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company pioneering novel CAR-T therapies and Tissue-Specific Therapeutics™ for hematologic cancers and autoimmune disorders. This page serves as the definitive source for verified corporate announcements, clinical development updates, and regulatory milestones.
Investors and researchers will find chronologically organized press releases detailing clinical trial results, FDA designations, and strategic partnerships. Our collection includes updates on lead candidates like NXC-201 for AL Amyloidosis and IMX-110 for soft tissue sarcoma, featuring their unique Single-Day CRS profiles and TME Normalization Technology advancements.
All content is curated to provide stakeholders with essential insights into the company’s progress in addressing unmet medical needs through innovative cell therapies. Regular updates ensure access to the latest information on trial phases, scientific publications, and intellectual property developments.
Bookmark this page for streamlined tracking of Immix Biopharma’s advancements in next-generation immunotherapy and biopharmaceutical research.
Immix Biopharma (NASDAQ:IMMX) announced the closing of an upsized underwritten registered offering on Dec 9, 2025 consisting of 19,117,646 shares of common stock at $5.10 per share and 490,196 pre-funded warrants at $5.09 each.
Net proceeds to the company after underwriting discounts, commissions and offering expenses were approximately $93.7 million. The financing included leading U.S. biotechnology institutional investors and mutual funds, with Morgan Stanley as sole book‑running manager and Citizens Capital Markets and Mizuho as co‑managers.
The securities were offered under a shelf registration statement (Form S-3, File No. 333-269100) declared effective Jan 11, 2023; a prospectus supplement was filed with the SEC and is available on the SEC website.
Immix Biopharma (NASDAQ:IMMX) priced an underwritten offering of 19,117,646 common shares at $5.10 each and pre-funded warrants to purchase 490,196 shares at $5.09 per warrant, for expected gross proceeds of $100 million.
The offering is expected to close on or about December 9, 2025, subject to customary closing conditions. Immix intends to use net proceeds to fund NXC-201 development, working capital and general corporate purposes, and says cash plus expected CIRM grant disbursements should fund operations into mid-2027. Morgan Stanley is sole book-runner; Citizens Capital Markets and Mizuho are co-managers. Securities are offered under a Form S-3 shelf registration.
Immix Biopharma (NASDAQ:IMMX) reported positive Phase 2 results for NXC-201 at ASH 2025 with an independent review committee complete response (CR) rate of 75% (15/20) at s/u IFE(-).
MRD negativity in bone marrow was observed in 4 of 5 pending patients, which the company says could raise the CR to 95%. Downstream organ responses occurred in 70% of evaluable patients (7/10). No neurotoxicity and only low-grade cytokine release syndrome (median duration 1 day) were reported. NEXICART-2 final readout and planned BLA submission in 2026. Data cutoff: Nov 13, 2025.
Immix Biopharma (NASDAQ:IMMX) appointed Michael Grabow as Chief Commercial Officer effective Nov 12, 2025 to lead U.S. commercialization and launch of NXC-201 in relapsed/refractory AL amyloidosis. The company highlighted Michael’s >25 years of commercialization experience and his role leading MODEYSO® go-to-market at Chimerix, which was acquired by Jazz for $935 million in 2025. Immix noted NXC-201 has received RMAT and Orphan Drug Designation from the FDA and positions a one-and-done approach for a disease with no currently approved FDA therapies.
Immix Biopharma (NASDAQ: IMMX) announced that interim Phase 1/2 results from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL amyloidosis were selected for an oral presentation at ASH 2025.
The oral presentation is scheduled for December 7, 2025, 5:45–6:00 PM ET (Abstract abs25-14730) in Session 652: MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias. The presentation covers first 20-patient safety and efficacy data from NEXICART-2, described as the first U.S. CAR-T trial in relapsed/refractory light-chain (AL) amyloidosis. Event details are available on Immix Biopharma’s investor presentations page.
Immix Biopharma (NASDAQ: IMMX) will present and host institutional investor meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA, November 10-12, 2025.
Management will participate in a Fireside Chat on November 11, 2025 at 12:30 PM ET and will be available for one-on-one meetings by request through Guggenheim representatives. A replay link will be posted on the company’s Investors > Presentation & Events page when available.
Immix Biopharma (NASDAQ:IMMX) will present an abstract for NXC-201 at the American Society of Hematology 67th Annual Meeting, December 6-9, 2025, in Orlando, Florida. The company, focused on relapsed/refractory AL amyloidosis, announced participation and an abstract presentation slot at the conference.
Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases, has announced its participation in the 37th Annual Piper Sandler Healthcare Conference.
The conference will take place on December 2-4, 2025 at the Lotte New York Palace Hotel in New York. The company will conduct institutional investor meetings and interested investors can arrange one-on-one meetings through their Piper Sandler representative. A replay of the presentation will be available on the company's website under the Investors section.
Immix Biopharma (NASDAQ:IMMX) has announced surpassing the 50% enrollment milestone in its NEXICART-2 clinical trial, evaluating NXC-201, a sterically-optimized CAR-T therapy for relapsed/refractory AL Amyloidosis.
The company is advancing toward its goal of achieving the first FDA-approved cell therapy Biologics License Application (BLA) for this orphan indication, where currently no FDA-approved treatments exist. The trial's interim results were presented at ASCO 2025 by Dr. Heather Landau of Memorial Sloan Kettering Cancer Center, with growing interest from clinicians and patients following the presentation.
Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company, has appointed Dr. Nancy T. Chang to its Board of Directors. Dr. Chang, former CEO of Tanox Inc., joins concurrent with her investment through Goose Capital.
Dr. Chang brings significant expertise, having led the development of several successful drugs including XOLAIR® for severe asthma, TROGARZO® for HIV, and EBGLYSS® for dermatitis. These drugs have collectively generated over $5 billion in sales. Notably, under her leadership, Tanox was acquired by Genentech/Roche for $919 million.
FAQ
What is the current stock price of Immix Biopharma (IMMX)?
What is the market cap of Immix Biopharma (IMMX)?
